BACKGROUND: Clinical and epidemiological studies suggest an association between cannabis use and psychosis but this relationship remains controversial. METHOD: Clinical high-risk (CHR) subjects (age 12-22 years) with attenuated positive symptoms of psychosis (CHR+, n=101) were compared to healthy controls (HC, n=59) on rates of substance use, including cannabis. CHR+ subjects with and without lifetime cannabis use (and abuse) were compared on prodromal symptoms and social/role functioning at baseline. Participants were followed an average of 2.97 years to determine psychosis conversion status and functional outcome. RESULTS: At baseline, CHR+ subjects had significantly higher rates of lifetime cannabis use than HC. CHR+ lifetime cannabis users (n=35) were older (p=0.015, trend), more likely to be Caucasian (p=0.002), less socially anhedonic (p<0.001) and had higher Global Functioning: Social (GF:Social) scores (p<0.001) than non-users (n=61). CHR+ cannabis users continued to have higher social functioning than non-users at follow-up (p<0.001) but showed no differences in role functioning. A small sample of CHR+ cannabis abusers (n=10) showed similar results in that abusers were older (p=0.008), less socially anhedonic (p=0.017, trend) and had higher baseline GF:Social scores (p=0.006) than non-abusers. Logistic regression analyses revealed that conversion to psychosis in CHR+ subjects (n=15) was not related to lifetime cannabis use or abuse. CONCLUSIONS: The current data do not indicate that low to moderate lifetime cannabis use is a major contributor to psychosis or poor social and role functioning in clinical high-risk youth with attenuated positive symptoms of psychosis.
BACKGROUND: Clinical and epidemiological studies suggest an association between cannabis use and psychosis but this relationship remains controversial. METHOD: Clinical high-risk (CHR) subjects (age 12-22 years) with attenuated positive symptoms of psychosis (CHR+, n=101) were compared to healthy controls (HC, n=59) on rates of substance use, including cannabis. CHR+ subjects with and without lifetime cannabis use (and abuse) were compared on prodromal symptoms and social/role functioning at baseline. Participants were followed an average of 2.97 years to determine psychosis conversion status and functional outcome. RESULTS: At baseline, CHR+ subjects had significantly higher rates of lifetime cannabis use than HC. CHR+ lifetime cannabis users (n=35) were older (p=0.015, trend), more likely to be Caucasian (p=0.002), less socially anhedonic (p<0.001) and had higher Global Functioning: Social (GF:Social) scores (p<0.001) than non-users (n=61). CHR+ cannabis users continued to have higher social functioning than non-users at follow-up (p<0.001) but showed no differences in role functioning. A small sample of CHR+ cannabis abusers (n=10) showed similar results in that abusers were older (p=0.008), less socially anhedonic (p=0.017, trend) and had higher baseline GF:Social scores (p=0.006) than non-abusers. Logistic regression analyses revealed that conversion to psychosis in CHR+ subjects (n=15) was not related to lifetime cannabis use or abuse. CONCLUSIONS: The current data do not indicate that low to moderate lifetime cannabis use is a major contributor to psychosis or poor social and role functioning in clinical high-risk youth with attenuated positive symptoms of psychosis.
Authors: Sagnik Bhattacharyya; Paul D Morrison; Paolo Fusar-Poli; Rocio Martin-Santos; Stefan Borgwardt; Toby Winton-Brown; Chiara Nosarti; Colin M O' Carroll; Marc Seal; Paul Allen; Mitul A Mehta; James M Stone; Nigel Tunstall; Vincent Giampietro; Shitij Kapur; Robin M Murray; Antonio W Zuardi; José A Crippa; Zerrin Atakan; Philip K McGuire Journal: Neuropsychopharmacology Date: 2009-11-18 Impact factor: 7.853
Authors: Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis Journal: Lancet Date: 2007-07-28 Impact factor: 79.321
Authors: Ángel Del Rey-Mejías; David Fraguas; Covadonga M Díaz-Caneja; Laura Pina-Camacho; Josefina Castro-Fornieles; Inmaculada Baeza; Ana Espliego; Jessica Merchán-Naranjo; Ana González-Pinto; Elena de la Serna; Beatriz Payá; Montserrat Graell; Celso Arango; Mara Parellada Journal: Eur Child Adolesc Psychiatry Date: 2015-03-01 Impact factor: 4.785
Authors: Sandra M Goulding; Carrie W Holtzman; Hanan D Trotman; Arthur T Ryan; Allison N Macdonald; Daniel I Shapiro; Joy L Brasfield; Elaine F Walker Journal: Child Adolesc Psychiatr Clin N Am Date: 2013-06-18
Authors: Jordina Tor; Montserrat Dolz; Anna Sintes; Daniel Muñoz; Marta Pardo; Elena de la Serna; Olga Puig; Gisela Sugranyes; Inmaculada Baeza Journal: Eur Child Adolesc Psychiatry Date: 2017-09-15 Impact factor: 4.785
Authors: Jean Addington; Nevicia Case; Majid M Saleem; Andrea M Auther; Barbara A Cornblatt; Kristin S Cadenhead Journal: Early Interv Psychiatry Date: 2013-11-14 Impact factor: 2.732